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Abstract
Successful mucosal administration and delivery of drugs still pose a great 
 challenge. However, the possibility to deliver not only small drug molecules but also 
macromolecular drugs and nanoparticles via mucosal surfaces represents a great 
opportunity. Rapid onset of drug action, avoidance of first-pass metabolism, and 
high immunocompetence of mucosa are some of the important features for mucosal 
drug and vaccine delivery. The use of mucoadhesive drug delivery systems, systems 
with fast dissolving properties, and nanomaterials with mucus penetration proper-
ties are examples of successful strategies to achieve effective mucosal drug and 
vaccine delivery. Non-keratinized mucosa of the oral cavity, the nasal and vaginal 
mucosa represent favorable sites of drug administration. Polymer nanofibers have 
attracted much attention because of remarkable characteristics such as a large sur-
face area to volume ratio and high porosity. Nanofibers have been extensively used 
for different biomedical applications including wound dressing, tissue engineering, 
and drug delivery. Among their fabrication methods, the introduction of electro-
spinning technique was an important step toward achieving the goal of large scale 
industrial production of nanofiber-based drug delivery systems used in mucosal 
applications. This chapter provides an overview on all aspects of mucosal drug and 
vaccine delivery using nanofibers.
Keywords: nanofibers, electrospinning, transmucosal drug delivery, mucoadhesive 
formulation, mucus penetration nanoparticles, first-pass metabolism, mucosal 
vaccines
1. Introduction
Mucosal drug delivery is an alternative method of systemic drug delivery that 
offers numerous benefits over/parenteral and oral administration. Mucosal sur-
faces, particularly oral, nasal, and vaginal, have been widely explored for systemic 
delivery of drugs. Drugs that are absorbed via mucosal surfaces directly enter 
the systemic circulation and bypass the gastrointestinal tract including first-pass 
metabolism in the liver. Rapid onset of drug action is another advantage of oral, 
nasal, and vaginal mucosae drug administration. A lot of efforts have been devoted 
to the discovery of efficient delivery of vaccine antigens to mucosal sites that 
enhance uptake by local antigen-presenting cells in order to generate protective 
mucosal immune responses. Potent mucosal adjuvants and suitable mucosal vaccine 
delivery systems are crucial steps on the way to effective mucosal vaccines.
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On the other hand, several challenges need to be overcome to successfully deliver 
drug molecules. Poor water solubility of numerous drugs, macromolecular nature 
of newly developed biologically active molecules, including therapeutic peptides, 
proteins, and nucleic acids, are some examples of challenging features that need to 
be overcome by developing new delivery approaches, devices, and dosage forms. 
Mucoadhesive drug formulations, rapidly disintegrating formulations, and for-
mulations with mucus penetration properties enabling mucosal delivery of such 
therapeutic molecules have made great progress over the last decade.
Anatomical and physiological functions of different types of mucosa need to 
be taken into consideration when formulating new drug delivery systems. These 
need to respect the flexibility of mucosal surfaces, the flow of body fluids such 
as saliva or vaginal fluid, ciliary movement on the nasal mucosa, presence of 
mucosal absorption barriers, including the mucus layer and keratinization of some 
surfaces, etc.
Nanofibers represent an interesting opportunity to tackle some of the difficul-
ties in mucosal drug delivery. Nanofibers represent an almost universal platform 
the properties of which can be tailored according to specific demands in terms of 
their composition as well as surface modifications. Advanced features of nanofibers 
include possible mucoadhesive properties, fast disintegration, controlled drug 
release, formulation of small drugs of different nature, and formulation of thera-
peutic macromolecules. These properties can help solve problems with mucosal 
delivery of poorly water-soluble drugs, drugs with fast liver metabolism, therapeu-
tic proteins, and antigens for mucosal immunization. Taken together, formulations 
based on nanofibers intended for mucosal applications represent a new trend in 
drug delivery.
2. Histology and barrier properties of mucosal surfaces
Histology, physiology, and barrier functions of mucosal surfaces play a criti-
cal role in mucosal drug and vaccine delivery. All aspects have to be taken into 
consideration when designing a mucosal drug delivery system. Also, appropriate 
drug candidates for mucosal delivery have to be selected, not only with respect to 
physical-chemical properties of drug molecule, but also anatomical and physiologi-
cal aspects of the intended site of administration and their deep knowledge are 
essential for successful delivery of drugs and vaccines.
2.1 Histology of mucosal surfaces
2.1.1 Oral mucosa
The mucosa of oral cavity is divided into the buccal, sublingual, gingival, 
palatal, and labial regions. The mucosa of each region is of specific histological and 
functional characteristics. Oral mucosa consists of three layers: a stratified squa-
mous epithelium, composed of several cell layers, below which lies the basement 
membrane, and finally the connective tissue divided into the lamina propria and 
submucosa, which comprise a number of vascular capillaries [1]. Drugs absorbed 
via the oromucosal route of administration are absorbed through these capillaries 
and gain access to the systemic circulation [2, 3].
Three major types of epithelium located in different regions of the oral cavity 
differ in the degree of keratinization, namely masticatory, specialized, and lining 
mucosa. The masticatory epithelium is keratinized (100–200-μm thick) and covers 
the gingival region and the hard palate. The specialized epithelium is stratified, 
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keratinized, and covers the dorsal surface of the tongue. The lining mucosa covers 
buccal and sublingual regions of the oral cavity. The epithelial layer of the buccal 
and sublingual mucosa is non-keratinized, with variation in thickness [4]. The lin-
ing mucosa exhibits high permeability for different drugs, and thus is an interesting 
site for drug administration.
The oral epithelium is covered by a 70–100-μm thick film of saliva, the secretion 
from salivary glands. The daily production of saliva secreted into the oral cavity is 
between 0.5 and 2 L. Continuous production of saliva significantly impacts drug 
residence time after administration within the oral cavity, a phenomenon known as 
saliva washout [5].
Mucus is the intercellular ground matrix secreted by the sublingual and salivary 
glands, which is bound to the apical cell surface and acts as a protective layer for the 
cells below [6]. It is also a viscoelastic hydrogel consisting of the water-insoluble 
glycoproteins, water, and small quantities of different proteins, enzymes, elec-
trolytes, and nucleic acids. The mucus layer carries a negative charge due to a high 
content of sialic acid and forms a strongly cohesive gel structure that binds to the 
epithelial cells.
The mucus layer varies in thickness from 40 to 300 μm. The mucus layer plays a 
critical role in the function of different mucoadhesive drug delivery systems which 
work on the principle of mucoadhesion, and thus prolong the dosage form retention 
time at the site of administration [7].
2.1.2 Nasal mucosa
The total surface area available in the human nasal mucosa is estimated to be 
about 180 cm2. Most of the surface is covered with highly vascularized respiratory 
mucosa and only a small surface area of the nasal cavity is covered by olfactory 
mucosa. Due to the presence of microvilli on the apical cell surface, the effective 
surface area for drug absorption is relatively high [8]. The nasal vestibule is lined 
by stratified squamous epithelium which gradually transitions in the valve region 
with a ciliated, pseudostratified, columnar epithelium characterized by presence 
of mucus-secreting goblet cells. Mucus lies over the epithelium as a protective 
layer and the mucociliary apparatus filters the air. Mucus is secreted at a flow rate 
of 5 mm/min and this fast renewal rate means that particles are eliminated from 
the nasal cavity in less than 20 min. The nasal mucosa is about 2–4-mm thick and 
composed of two distinct layers: periciliary layer and superficial layer [5, 9].
Enzymes and peptidases contained in the mucus, its constant secretion, and 
nasal clearance mechanisms significantly reduce the ability of drugs to penetrate 
through the epithelium [10]. Studies have shown that rapid systemic delivery of 
topically applied drugs can be achieved after intranasal administration due to the 
permeable properties of the respiratory epithelia and highly vascularized nature of 
the adjacent submucosa.
Immunologically specialized region localized at the gateway of the respira-
tory and alimentary tract consists of the palatine tonsils, nasopharyngeal tonsils 
(adenoid), lingual tonsils, and tubal tonsils and is designated as Waldeyer’s ring or 
nasal-associated lymphoid tissue (NALT). It represents a site of intimate contact 
between exogenous antigens and the host aerodigestive tract. With exception of 
adenoids and tubal tonsils covered by pseudostratified ciliated columnar epi-
thelium (respiratory epithelium) the palatine and lingual tonsil are covered by 
stratified non-keratinized squamous epithelium with many invaginations allowing 
the enhanced exposure of foreign antigens to the underlying cryptal lymphatic 
tissue. Therefore, nasal mucosa is one of intensively explored sites for vaccine 
administration.
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2.1.3 Vaginal mucosa
The vaginal mucosa is composed of four histological layers: the stratified 
squamous epithelium (with underlying basement membrane), the elastic lamina 
propria (a dense connective tissue layer which projects papillae into the overlying 
epithelium), the fibromuscular layer comprising two layers of smooth muscle, and 
the tunica adventitia, consisting of areolar connective tissue [5].
The vaginal epithelium is composed of non-cornified, stratified squamous cells. 
Several layers of cuboidal cells are close to the basement membrane and become 
flattened as they move toward the luminal surface. The thickness of vaginal epithe-
lium is around 200–300 μm, and is influenced by physiological factors, e.g., vari-
ability in estrogen concentration [11].
Vaginal surface is coated with a layer of cervicovaginal fluid. The fluid contains 
secretions from the cervix in the form of mucins and secretions from the Bartholin’s 
and Skene’s glands, endometrial fluid, and fluid transuded from the vascular bed 
of the vaginal tissue. It also contains a large number of squamous epithelial cells, 
enzymes, proteins, carbohydrates, and amino acids. The acidic vaginal environment 
is maintained by production of lactic acid by lactobacilli but the exact pH value is 
influenced by the presence of cervical mucus, the amount of vaginal fluid, infec-
tions, and other factors. Cervical mucus forms a semipermeable viscoelastic barrier 
at the vaginal surface. High constant production of cervicovaginal fluid influences 
the properties of different drug delivery systems, the residence time after adminis-
tration as well as the rate of drug release and absorption [12].
2.2 Barrier functions of mucosal surfaces
2.2.1 Oral mucosa
The rate of drug absorption following oromucosal administration is influenced 
by the permeability of the buccal and sublingual mucosa, physical-chemical prop-
erties of the delivered drug, and other factors, namely the presence and properties 
of mucus, saliva production, movement of the oral tissues during speaking, food 
and drink intake, etc. The mucus layer is the main natural barrier of mucosa against 
penetration of different pathogens and foreign particles. One the other hand, 
mucus layer is one of the main absorption barriers to a variety of drugs, including 
nanoparticle-based drugs and vaccine formulations [5].
Drug permeability through the oral cavity mucosa represents a major limiting 
factor in transmucosal drug delivery. Mechanically stressed areas are keratinized 
and impermeable to water, which makes such areas unfavorable for drug delivery. 
On the other hand, more permeable non-keratinized buccal and sublingual epithe-
lia make such regions of the oral cavity attractive sites for drug delivery and a great 
number of active ingredients are currently being explored in terms of transmucosal 
drug delivery [13].
One of the main permeability barriers of oral mucosa is represented by the 
presence of a layer of extracellular lipidic material coming from membrane-coating 
granules (MCGs). They are present in both keratinized and non-keratinized epithe-
lia, but the composition of lipidic material is different between the two types [14].
Passive diffusion of drugs and drug carriers through mucosal surfaces is gener-
ally considered the primary mechanism responsible for the transport of drugs 
across the oral mucosa [15]. However, active transport mechanisms are connected 
to the activity of different types of immune cells widely present in oral mucosal 
tissues, especially in sublingual and buccal regions. Such immune cells, mainly 
different types of dendritic cells, act as an immunological barrier between the body 
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and foreign stimuli (including pathogens and potential allergens), mainly com-
ing to the body with food and drink. These cells are responsible for tolerogenic, or 
opposite reaction to such stimuli.
Another barrier to drug permeability across oromucosal surfaces is enzymatic 
degradation. Saliva contains some enzymes that are able to metabolize some peptide 
and protein therapeutics. This fact leads to reduced bioavailability of protein-based 
therapeutics after oromucosal administration.
The flow of saliva makes it difficult for a drug delivery system to retain the 
released drug at the site of administration and, therefore, mucoadhesive drug 
formulations are the preferred dosage form for oromucosal drug delivery [5].
2.2.2 Nasal mucosa
The main barrier functions of nasal mucosa include the role of the mucus layer 
and the process of mucociliary clearance. For systemically acting drugs, the mucus 
layer acts as a diffusion barrier. The rate of the diffusion through the mucus layer 
is dependent on several factors involving thickness and viscosity of the mucus, 
and drug physical-chemical properties. The thickness of the layer of mucus in the 
nasal cavity is a few microns and, therefore, in contrast to other mucosal surfaces, it 
does not represent a substantial diffusion barrier. The rate of mucociliary clearance 
influences the contact time of epithelia and a drug delivery formulation and also the 
drug molecules themselves [9].
Transport across epithelial barriers with respect to the nasal route, and drug 
permeation via the paracellular route are limited because of the presence of tight 
junctions. Therefore, passive diffusion via the transcellular route is the main trans-
port pathway across the nasal epithelium [16].
Physical-chemical factors that influence nasal drug absorption are the molecular 
weight and lipophilicity. Polar and ionized molecules show poor permeability. On 
the other hand, drugs with systemic action currently administered by the intranasal 
route are of low molecular weight and lipophilic nature. Moreover, some thera-
peutic peptides, e.g., salmon calcitonin and oxytocin, also exhibit some level of 
systemic nasal absorption [5].
2.2.3 Vaginal mucosa
Properties of the vaginal epithelium such as thickness and barrier functions are 
depending on several factors, including age and hormonal activity [12]. The above 
mentioned factors affect both vaginal fluid production and the amount of enzymes 
contained in the fluid. The surface of vaginal epithelium contains a variety of 
enzymes which can metabolize the delivered drugs, especially therapeutic peptides 
and proteins. The present proteases are the main barrier for absorption of such 
drugs into the blood as they are degraded before they cross the epithelium and 
can reach systemic circulation. Cervicovaginal fluid acts as a dissolution medium 
that enables transfer of drugs from the dosage form into the tissue. It has also 
been claimed that drugs can directly be transferred from dosage form to epithelial 
tissues. This means that a portion of the released drug molecules can overcome the 
fluid compartment. The pH in the vagina is around 4, thus strongly acidic under 
normal conditions. These conditions can lead to rapid drug degradation.
Systemic mucosal delivery through vaginal epithelium has several advantages, 
including ease of administration, avoidance of drug liver first-pass metabolism, rela-
tively low metabolic activity, high permeability, prolonged retention, and the poten-
tial for sustained release from drug delivery formulations with controlled release 
properties. Important physical-chemical properties of drugs delivered through 
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vaginal mucosa include drug solubility in the vaginal fluid, tissue permeability, 
chemical stability of drugs under certain pH conditions, and drug lipophilicity [5].
2.3 Mucosal vaccines
Mucosal surfaces, such as those of the respiratory, gastrointestinal, and genital 
tracts, act as the first line of defense against environmental pathogens. Although 
immunization by mucosally applied vaccines has had a long history with numerous 
micro-organisms and a variety of administration routes, only a few such vaccines 
are currently used in human medicine. Nevertheless, these examples (e.g., polio-
myelitis, influenza, cholera, Salmonella typhi) clearly demonstrate the validity of 
this strategy. There are many reasons for the development of mucosal vaccines as 
an attractive alternative to those administered by systemic routes. Most impor-
tantly, protective immune responses can be induced at the relevant mucosal sites of 
pathogen entry by mucosal delivery of vaccines, and thus the enormous potential 
of immunity in mucosal tissues and their associated secretory glands remains to be 
exploited in vaccinology. Better understanding of mucosal immune system together 
with new nanomaterials, including nanofibers and engineering of recombinant 
antigens, enhanced a long-lasting effort to develop mucosal vaccines capable of 
effectively inducing both mucosal and systemic immune responses, thereby result-
ing in two layers of host protection.
Mucosal vaccination, in contrast to other routes of vaccine administration, is of 
particular interest since it can enhance immune responses, mainly secretory IgA, 
which defends the portal of entry of various infectious pathogens [17]. Since the 
route of vaccine administration has a significant effect on the resultant immune 
response, much effort has been made to explore novel mucosal vaccine delivery 
routes, briefly described in this chapter.
The noninvasive needle-free vaccine delivery mode (nonparenteral routes of 
application) has become a global priority, both to eliminate the risk of improper and 
unsafe needle use and to simplify vaccination procedures. Development of alterna-
tive vaccine delivery methods, including mucosal routes, becomes a prominent field 
of vaccine research and represents a challenge for new biocompatible materials, 
especially nanomaterials. The vaccine administration route significantly affects 
immune responses regarding the intensity and quality (class-specified Ig, TH1/TH2 
balance, anergy).
Furthermore, for vaccination campaigns organized to stop epidemics of muco-
sally transmitted infections, mass immunization by mucosal routes is likely to be 
more practicable and less expensive than immunization by systemic routes. In 
addition, many parents already hesitate to subject their young children to repeated 
needle sticks. The factors like reduced cost of mucosal vaccines must be taken into 
consideration. Economy of mucosal vaccines is based on both production/distribu-
tion and application levels. The purity of mucosally delivered vaccines, including 
endotoxin contamination, is less critical than for injectable vaccines. Finally, 
mucosal vaccine delivery does not require sterile syringes and needles or personnel 
trained in their use and disposal, although spray devices or other applicators may 
be needed for intranasal and other routes of administration. From this point of 
view, sublingual application of vaccines represents the easiest and the most favor-
able modes.
Nevertheless, there are some drawbacks in terms of mucosal vaccination, 
particularly the uncertainty of the amount of effectively delivered antigen follow-
ing its mucosal administration. Another problem is the limited uptake of intact 
protein and polysaccharide antigens at mucosal surfaces. Moreover, potential for 
degradation of antigens, especially in the gastrointestinal tract following oral 
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administration is another issue. Therefore, as compared to oromucosal administra-
tion, significantly higher doses of vaccine antigens must be administered orally 
to induce measurable immune responses. To overcome such difficulties, various 
particulate antigen delivery systems have been designed.
Successful development of future mucosal vaccines is based on three basic pil-
lars critical for inducing the effective immune response. These pillars are adjuvants, 
application/delivery systems, and antigens.
Adjuvants represent one of the key issues in all vaccine development. The 
identification and development of appropriate mucosal adjuvants to enhance the 
desired aspects of the immune response against the antigens represent a special 
challenge because adjuvants for mucosal application involve requirements different 
from those for parenteral use. On the other hand, this affords greater opportunities 
for discovery by exploiting the growing understanding of the mechanisms whereby 
mucosal pathogens and commensals interact with the immune system. Cholera 
toxin (CT) and related heat-labile enterotoxins such as Escherichia coli labile toxin 
(LT) are classic examples of mucosal adjuvants for their ability to break immune 
tolerance [18]. A major concern for human application has been to separate the 
toxicity of these molecules from their adjuvant properties. Different approaches 
were used based on targeted mutations in the enzymatically active site of the A sub-
unit, the selection of various types of toxins including mutants that have different 
ganglioside (receptor)-binding B subunits and the use of nontoxic B subunits alone 
or coupled to vaccine antigens. Intranasal administration has generated interest and 
concern with the finding that CT and LT can undergo retrograde migration along 
neurons, potentially reaching the brain via the olfactory nerve, and thus leading 
to neurological pathology. An intranasal influenza vaccine which contained a low 
dose of LT as an adjuvant was introduced in Switzerland, but it was withdrawn due 
to suspicion of causing Bell’s palsy in some recipients [19]. Facial nerve palsy was 
another side effect demonstrated after intranasal application of a flu vaccine. As an 
alternative route, sublingual vaccination has been demonstrated to achieve similar 
immune responses but without the risk of retrograde transmission to the brain [20].
Other molecules derived from microorganisms and falling into the category 
of pathogen associated molecular pattern (PAMP) have also been shown to have 
immunomodulatory properties. Ligand for Toll-like receptors, NOD1/2 receptors, 
and inductors of inflammasomes are examples of such molecules (e.g., monophos-
phoryl lipid A, “CpG” oligodeoxynucleotides, muramyl glycopeptides, flagellin). 
Nevertheless, none of these has been investigated as extensively as the heat-labile 
enterotoxins.
Delivery systems for mucosal immunization are functionally related to adjuvants 
for mucosal vaccines as well as to antigen formulations. The principal task for 
delivery systems is to keep antigen on mucosal surface and to enhance its penetra-
tion into submucosal tissue to be accessible in sufficient amount to immune cells, 
especially to dendritic cells. Various gels and films are available for buccal applica-
tion of drugs, while sprays or droplets are used for intranasal application of influ-
enza vaccines. Oral application of vaccines is achieved mainly by various capsules 
containing antigens or simply by administration of the vaccine on a spoon (polio).
While some formulations for nasal and oral delivery of vaccines are avail-
able, suitable delivery systems for sublingual vaccination are at their door step of 
development. In this chapter, we describe the mucoadhesive nanofiber-based film 
fulfilling the role of delivery system for sublingual immunization. This system is 
compatible with antigens formulated as proteoliposomes and immunostimulat-
ing complexes (ISCOMs), virus and virus-like particles, bacteria and bacterial 
ghosts, plasmid DNA, polymeric nanoparticles, and a simple free antigen. Such 
formulations also allow the sustained release of vaccine antigens and provide some 
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protection against removal from the site of application by saliva flow and tongue 
movement. Also, enhancers of mucosal penetration can be combined with antigens 
and mucosal adjuvants, which make the mucoadhesive nanofiber-based films a 
universal platform for mucosal sublingual vaccination. The important aspect of the 
mucoadhesive nanofiber-based film is its suitability for industrial production as the 
crucial factor of pharmacoeconomy [21].
In conclusion, sublingual immunization represents the route of a big hidden 
potential for development of effective, cheap, and safe vaccines for prevention of 
infectious diseases as well as the treatment of allergy.
2.4 Penetration enhancers
Penetration enhancers, sometimes also referred to as chemical enhancers, are 
functional pharmaceutical excipients that possess the ability to modify the physical-
chemical properties of mucosal barriers. The reason for co-administration of 
penetration enhancers is to enhance penetration of drugs through different barriers 
of mucosa including mucus layer, extracellular lipid layer originating from MCGs, 
enzymatic barrier, and others. The target compartment of the delivered drug can dif-
fer according to the mode of its action, e.g., blood circulation in systemic drug deliv-
ery, specialized immune cells present in epithelium or submucosal tissue in vaccine 
delivery and local cell therapy, etc. Penetration enhancers can potentially facilitate the 
systemic absorption of a wide range of drugs, including large therapeutic molecules 
such as polypeptides, proteins, nucleic acids [22], and therapeutic nanoparticles.
Different surfactants, bile salts (deoxycholic, ursocholic, and taurocholic acids), 
ethylenediaminetetraacetic acid (EDTA), fatty acids, and amino acids are the most 
frequently explored chemicals used in mucosal enhancing of drug permeability, 
and thus its bioavailability [23, 24]. An important concern related to penetration 
enhancers is the capacity of adjacent tissues to tolerate the effects of penetration 
enhancers.
Penetration enhancers act usually by a combination of different mechanisms. 
Some penetration enhancers are amphipathic in nature, and thus associate and 
influence bilayers of the cell membranes, increase the fluidity and permeability 
of membranes and finally promote transcellular transport. Penetration enhancers 
can interact with tight junctions between epithelial cells that cause facilitation of 
paracellular drug transport. Another group of penetration enhancers, known as 
mucolytic agents (e.g., acetylcysteine) influence the integrity of the mucus layer.
Formulation of drugs into nanofibers, especially nanofibers with mucoadhesive 
properties, enhances drug absorption via mucosal surfaces in general. Moreover, 
combination of nanofiber-based formulations and chemical enhancers can increase 
penetration of drug molecules, or nanoparticle-based drug and vaccine delivery 
systems. Nanofibers themselves have extraordinary capacity to combine different 
types of chemicals including combination of drugs and penetration enhancers, 
whether using electrospinning technique for nanofiber production, or another 
technique. As an example, mucosal penetration of model mucus penetration 
poly(lactic-co-glycolic) acid (PLGA) nanoparticles from nanofiber-based mucoad-
hesive film into porcine sublingual and buccal mucosa was enhanced using sodium 
deoxycholate as penetration enhancer [21].
3. Transmucosal delivery of drugs and vaccines
Different parts of the human body are covered by mucosa with different fea-
tures and barrier properties for drug delivery. Some areas are more accessible than 
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others. In principle, there are two ways of mucosal drug delivery—local delivery, 
e.g., antimicrobials, anti-inflammatory drugs, etc., and systemic drug delivery. 
Whereas many indications for drugs intended for local treatment exist and include 
all mucosal surfaces, systemic drug delivery is a completely different task and only a 
few parts of mucosa are suitable sites for systemic drug administration and absorp-
tion. Moreover, only several drugs with suitable physical-chemical properties have 
been administered via transmucosal delivery. On the other hand, mucosal drug 
absorption has enormous potential, and different strategies including penetration 
enhancers, nanoparticle-based drugs, and mucoadhesive drug formulations have 
been employed.
Because of easy accessibility, high vascularization and a relatively low thickness, 
oral mucosa, especially its sublingual and buccal parts, is a preferred site of sys-
temic drug administration. Transmucosal delivery of certain drugs can result in a 
rapid onset of their action, thus having the potential to replace the injection admin-
istration of some specific drug molecules [25]. Oromucosal delivery of nitroglycerin 
brings many benefits for patients, and today, nitroglycerin is one of the most 
frequent drug molecules delivered via oral mucosa. Exploration of cardiovascular 
drugs (e.g., captopril, verapamil) has shown promising results. Oral transmucosal 
delivery of analgesics has attracted substantial attention. As an example, oromuco-
sally administered fentanyl is designed for rapid noninvasive delivery of analgesia 
for severe pain treatment.
Oromucosal delivery of sedatives and hypnotics has shown favorable results 
with clinical advantages over other routes of administration. Another example is 
drugs for erectile dysfunction and transmucosal formulations of hormones, e.g., 
testosterone and estrogen. Transmucosal spray formulation of insulin (Oral-lyn®, 
Generex) is a great example of the potential of oral mucosa for systemic macromo-
lecular drug delivery.
Transmucosal nasal drug delivery is another interesting site for systemic drug 
delivery. The considerable blood supply of nasal mucosa provides efficient systemic 
drug absorption and enables direct access to the systemic circulation for drugs. In 
nasal drug delivery, limited nasal capacity often results in partial swallowing of 
the instilled drug as the instilled volumes exceed the limited capacity of the nasal 
mucosa. Therefore, the administered dose of the drug is partially swallowed, and 
drug absorption is in part transmucosal, in part gastrointestinal. Formulation of 
drugs into different mucoadhesive dosage forms and nasal inserts can be beneficial 
in this regard. Several drugs have been successfully administered including active 
ingredients with hormonal activity (salmon calcitonin, oxytocin, desmopressin) 
and small drugs (e.g., sumatriptan, zolmitriptan, dihydroergotamine).
As nasal mucosa is the first barrier which must be conquered by pathogens, 
nasal mucosa is very immunocompetent. Many studies have shown that even small 
amounts of antigen can elicit a strong protective response. Intranasal administra-
tion, similarly to oromucosal, seems to be the best strategy for barrier vaccinations 
following the outbreak of highly infectious diseases, because less erudite persons 
(e.g., nurses) can provide mass vaccination. FluMist® (US) and Fluenz® (Europe) 
are examples of live attenuated influenza vaccines.
The vaginal mucosa offers many advantages as a site for drug delivery, including 
easy access, prolonged residence time interval of drug availability, avoidance of 
first-pass metabolism, and relatively low activity of proteases and other enzymes. 
The vagina has a rich vascularization and a large surface area due to the folds 
in the mucosa (rugae) making it ideal for high absorption of drug molecules. 
Administration of drugs through vaginal mucosa represents an interesting alterna-
tive to oral administration for drugs treating osteoporosis, hormone replacement 
therapy, contraception, infections, and others. Mucoadhesive polymers are often 
Nanomaterials - Toxicity, Human Health and Environment
10
used in formulations for vaginal drug delivery systems to prolong retention time of 
drug delivery systems [26].
Mucosal immune responses in the genital tract can be induced by the admin-
istration of antigen to mucosal surfaces. IgA antibodies in the vaginal tract are 
essential as a first line defense against pathogens that enter the body through 
vaginal mucosa. Immune responses of various types of vaginally administered vac-
cines have been investigated. Both vaginal and serum IgA and IgG levels have been 
enhanced following vaginal vaccine administration [27].
The nasal mucosa vaccination induces preferentially mucosa-associated immune 
responses. There are several vaccination approaches to induce both mucosal and 
systemic immune responses (antibodies and cell-mediated immunity), for example 
by heterologous immunization by systemic followed by mucosal routes. Combining 
of parenteral and mucosal administration of antigen is required because parenteral 
vaccines are notoriously inefficient for stimulating immune responses in mucosal 
tissues; and on the other hand, mucosal vaccination, particularly that administered 
by oral route to subjects without antecedent contact with vaccination antigen 
leads to induction of the “oral tolerance” phenomenon consisting in induction 
of IgA-mediated immune responses in mucosal compartments but dominantly 
cell-mediated antigen-specific tolerance in systemic compartment. In contrast, 
sublingual (SL) vaccination represents a route effectively stimulating both systemic 
and mucosal antibody- and cell-mediated immune responses. Sublingual mucosa is 
the place of vaccine administration which in contrast to other mucosally effective 
intranasal routes does not elicit neurotoxic effects as demonstrated for example 
with inactivated influenza virus administered SL together with a mucosal adju-
vant which did not migrate to or replicate in the nerve system [28]. Furthermore, 
sublingual mucosa may be useful as a delivery site for mucosal vaccines because the 
sublingual epithelium harbors a dense lattice of dendritic cells (DC), and that using 
mucosal adjuvants mobilizes DCs within the sublingual epithelium. These cells 
migrate to the above mentioned proximal draining lymph nodes (submaxillary and 
superficial cervical lymph nodes), on uptake of the sublingual vaccine antigens. 
It is important that sublingual immunization induces antigen-specific immune 
responses in the female reproductive tract in addition to the respiratory tract and 
oral/nasal cavity [29]. Another mucosal administration route, orogastric route, can 
induce strong mucosal responses, especially secretory IgA in the small intestine, 
proximal colon, and mammary and salivary glands but it is poorly efficient for dis-
seminating these responses to the distal segments of the gut and to the respiratory 
and reproductive tracts. Moreover, orogastric immunization requires substantially 
more antigen application because of intensive degradation. In addition to orogas-
tric, nasal, and sublingual vaccines, transcutaneous immunizations are now part of 
a new generation of mucosal vaccines [30].
4. Nanofibers in mucosal drug delivery applications
4.1 Mucoadhesion and mucoadhesive properties of nanofibers
Mucoadhesion is defined as adhesion between a mucosal surface and a surface of 
another material. Mucoadhesive dosage forms have recently attracted much atten-
tion from pharmaceutical research as well as from pharmaceutical industry due to 
substantial improvements in mucosal drug delivery. Increasing the residence time 
of drug formulations at the site of administration automatically leads to much more 
effective transmucosal drug delivery, drug bioavailability, and results in increased 
therapeutic efficiency, thus lowering the drug dose needed [13]. Instead of small 
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drug molecules, mucoadhesive formulations enable delivery of therapeutic biologi-
cals such as peptides, proteins, antibodies, and nucleic acids through a variety of 
routes of administration such as oromucosal, ocular, nasal, and vaginal. Moreover, 
mucosal delivery of nanoparticle-based therapeutic formulations can be achieved 
by materials with mucoadhesive properties, mucus penetration formulations, and 
their combinations. Taste masking properties are of importance for mucoadhesive 
formulations intended for oromucosal administration.
Nanofibers made up of mucoadhesive polymers exhibit one of new trends in 
mucosal drug delivery. Due to their extremely large surface area, unique surface 
topology, and porosity, nanofibers are known to significantly improve the adhe-
siveness of the mucoadhesive drug delivery systems utilizing nanofibers for their 
construction. Architecture of nanofibers significantly intensifies the intimate 
contact between the nanofiber-based products and mucosal surface, and high drug 
concentration at the site of administration is achieved (Figure 1). Moreover, their 
ability to enhance drug solubility makes nanofibers an almost ideal platform for 
transmucosal drug delivery.
The use of mucoadhesive polymers is conditioned by their ability to form 
nanofibers. A variety of factors affect the ability of polymers to form nanofibers 
as well as the mucoadhesive properties of polymers, including molecular weight, 
chain flexibility, hydrogen bonding capacity, cross-linking density, charge and 
degree of ionization of a polymer, concentration, and hydration (swelling) of a 
polymer [3].
These are reasons why only a few mucoadhesive polymers have been tested for 
nanofiber-based drug delivery system formulations. Chitosan (cationic polymer), 
hyaluronic acid, sodium alginate, sodium carboxymehylcellulose (anionic poly-
mers), different cellulose derivatives, poly(ethylene oxide), and polyvinylpyrrol-
idone (nonionic polymers) are excellent examples of conventional mucoadhesive 
materials utilized for construction of nanofiber-based mucoadhesive drug delivery 
systems. A group of thiolated polymers, e.g., thiolated chitosan, are representatives 
of next-generation mucoadhesive materials [3, 13]. Mucoadhesive nanofibrous 
membrane made of chitosan/PEO is visualized in Figure 2 as an example.
Figure 1. 
Schematic representation of drug and vaccine delivery after mucosal administration of nanofiber-based drug 
delivery system.
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4.1.1 Chitosan
Chitosan is a linear polysaccharide composed of randomly distributed 
D-glucosamine and N-acetyl-D-glucosamine obtained by deacetylation of chitin 
(Figure 3). Because of the broad chemistry of chitosan, which covers different 
degrees of deacetylation, a range of molecular weights and different distribution 
of the acetyl groups along the polymeric chain, chitosans can provide a number of 
physical-chemical as well as biological properties. Mucoadhesion of chitosan occurs 
due to the electrostatic interactions of amino groups of chitosan and the sialic 
groups of mucin in the mucus layer.
Several studies have explored mucoadhesive properties of chitosan-based nano-
fibers. As an example, Lancina et al. have produced chitosan-based nanofiber mats 
capable of delivering insulin via the buccal mucosa. Chitosan was electrospun into 
nanofibers using poly(ethylene oxide) (PEO) as a carrier molecule. Insulin release 
rates were determined and showed no reduction in bioactivity due to electrospin-
ning. Buccal permeation of insulin was significantly facilitated as compared to free 
insulin. Taken together, this work demonstrates that chitosan-based nanofibers 
have the potential to serve as a transbuccal insulin delivery vehicle [31]. In another 
study, mucoadhesive fibers of zein/chitosan have been prepared by electrospinning 
to study the encapsulation efficiency and release of tocopherol. The addition of the 
acidic chitosan solution to the zein containing tocopherol has improved the muco-
adhesive properties of the final composite nanofibers [32]. Mucoadhesive hybrid 
Figure 3. 
Structural formula of chitosan.
Figure 2. 
Electrospun nanofibrous membrane fabricated using Nanospider technology (A) and detail of mucoadhesive 
chitosan/PEO nanofibers (B).
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electrospun chitosan/phospholipid nanofibers intended for drug-delivery applica-
tions were produced by Mendes et al. [33]. Nanofibrous membranes intended for 
local delivery of an antimicrobial agent in combination with poly(hexamethylene 
biguanide) hydrochloride were produced by electrospinning of chitosan/PEO 
solution. Inhibition of bacterial growth for both Escherichia coli and Staphylococcus 
aureus were achieved using nanofiberous membranes [34].
4.1.2 Cellulose derivatives
Cellulose (Figure 4) mucoadhesive derivatives are a wide group of pharmaceuti-
cal excipients and cover both nonionic polymers, including hydroxypropylmethyl-
cellulose (HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), 
methylcellulose (MC), and anionic derivatives, e.g., carboxymethylcellulose (CMC).
The aim of the study exploring carboxymethylcellulose as a mucoadhesive agent 
for nanofiber formation was to develop a progesterone-loaded mucoadhesive system 
for vaginal application with sustained release. Presently, two dosage form options 
are being considered: direct compression of nanofibers into tablets for vaginal 
insertion and winding bundles of the fiber into a miniature tampon [35, 36].
In another work, nanofiber-based indomethacin films were prepared using 
different grades of methylcellulose, polyvinylpyrrolidone, and Tween® 80 by 
electrospinning. The addition of Tween® 80 to polyvinylpyrrolidone formula-
tions significantly improved their wettability. Moreover, nanofiber-based patches 
containing methylcellulose and Tween® 80 were found to exhibit the highest 
permeation of indomethacin across porcine mucosa without significantly affecting 
the ultrastructure of the oral mucosa [37].
El-Newehy et al. demonstrated the preparation of HPC-based nanofibers. They 
found that the thermal stability and mechanical properties of nanofiber mats were 
dramatically enhanced with the addition of HPC to polyvinyl acetate or polyvinyl-
pyrrolidone. The in vitro sustained release of an incorporated model drug, diclof-
enac sodium, was controlled when loaded into electrospun nanofibers of HPC with 
either PVA or PVP [38].
4.1.3 Poly(ethylene oxide)
Mucoadhesive glutamine-loaded poly(ethylene oxide) (Figure 5) electrospun 
nanofibers were prepared by Tort et al. The effect of different polyelectrolytes on 
resultant properties of nanofibers was observed. 85% of the drug was released from 
the nanofibers after 4 h in simulated saliva solution suggesting that glutamine-
loaded nanofibers have potential as an oromucosal drug delivery system [39].
Figure 4. 
Structural formula of cellulose.
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Nanofiber-based local drug delivery system may be suitable for the treatment of 
cervical cancer. A pilot study by Zong et al. was carried out to examine the efficacy 
of cisplatin-loaded poly(ethylene oxide)/polylactide composite electrospun nano-
fibers as a local chemotherapy system against cervical cancer in mice via vaginal 
implantation. They have shown that a better balance between antitumor efficacy 
and systemic safety was achieved in a group of animals treated with nanofiber 
formulation as compared to i.v. injection group using an equal drug dose. Therefore, 
electrospun nanofibers present a promising approach to the local drug delivery via 
vaginal mucosa against cervical cancer [40].
4.1.4 Thiolated chitosan
Thiolated polymers are obtained by the addition of conjugated sulfhydryl 
groups. Thiolation of chitosan increases their mucoadhesive properties due to 
formation of disulfide bridges with cysteine domains of glycoproteins of the mucus. 
Moreover, chitosan and thiolated chitosan possess antiprotease activity due to their 
affinity to divalent cations, which are co-factors for proteases. All these character-
istics make thiolated chitosan a promising material for mucosal administration of 
drugs, peptides, and proteins [13].
Leila Behbood et al. developed mucoadhesive nanofibers made up of thiolated 
chitosan as a drug delivery system for tetracycline and triamcinolone. Chitosan was 
modified via the immobilization of thiol groups from L-cysteine as a mucoadhesive 
reagent. Maximal mucoadhesion of nanofibers was observed at the pH value of 6. 
Release studies demonstrated that a sustained release of both drugs continued up 
to 48 h. The drug delivery system represented a novel tool for the improvement of 
therapeutic efficacy of various drugs that are poorly absorbed from different parts 
of the gastrointestinal tract. It was also shown to be an efficient system for treat-
ment of oral ulceration [41].
The aim of the study performed by Samprasit et al. [42] was to fabricate muco-
adhesive electrospun nanofiber mats containing α-mangostin for the maintenance 
of oral hygiene and reduction of the bacterial growth. Thiolated chitosan blended 
with polyvinyl alcohol was selected as the mucoadhesive polymer. The results of 
this study suggest that α-mangostin-loaded mucoadhesive electrospun nanofiber 
mats may be a promising material for the prevention of dental caries.
4.2 Transmucosal delivery of poorly soluble drugs using nanofibers
Many drugs are highly hydrophobic with poor water solubility and the number 
of poorly water-soluble drug candidates selected for development is rapidly increas-
ing. It results in low oral absorption of these drugs as the absorption and bioavail-
ability are limited by their poor solubility or slow dissolution in the gastrointestinal 
tract. This represents a major challenge for the pharmaceutical industry and novel 
Figure 5. 
Structural formula of poly(ethylene oxide).
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formulation approaches are required. Several strategies including particle size 
reduction, micellization, salt formation, complexation, and solid dispersions have 
been developed to increase the oral absorption of such drugs. Solid dispersion is 
defined as the dispersion of one or more drugs in an inert matrix in the solid state. 
Simple eutectic mixtures, solid solutions, glass solutions of suspensions, and amor-
phous precipitates of a drug in a crystalline carrier are examples of solid dispersions 
[43]. Due to difficulties occurring during conventional methods of drug formula-
tion, the applicability of solid dispersion systems has remained limited. Electrospun 
nanofibers provide a novel approach to improve the dissolution rate of even poorly 
water-soluble drugs, and thus might minimize the limitations of oral and oromuco-
sal drug bioavailability [44].
As an example, maraviroc, an anti-HIV drug intended for intravaginal adminis-
tration, was electrospun as solid dispersion made from either polyvinylpyrrolidone 
or poly(ethylene oxide) nanofibers or microfibers. In the study, the role of drug 
loading, distribution and crystallinity in determining drug release rates into aque-
ous media was investigated. It was shown that water-soluble electrospun materials 
can rapidly release maraviroc upon contact with moisture and that drug delivery is 
fast [45].
Salt formation improves drug solubility. However, drugs administered onto 
mucosal surfaces are effectively absorbed through mucosal surfaces if they are in 
the unionized form. Therefore, this strategy of enhanced drug dissolution is not 
advantageous for mucosal drug delivery.
The rate of dissolution of drugs formulated into particles is increased with their 
increasing surface area and decreasing particle size. Technologies used to decrease 
drug particle size to sub-micrometer range are being frequently applied to poorly 
water-soluble drug product development. Electrospinning is one of the technologies 
that can produce uniform nanosized polymeric nanofibers with drugs loaded into 
their structure. The release rates, and thus bioavailability of nanofiber-formulated 
drugs, are enhanced compared to those from the original drug substance [46].
Oral mucosa provides an interesting site of drug administration and absorption 
including poorly water-soluble drugs. However, they are not usually suitable for 
the formulation into classical oromucosal drug delivery systems. The formulation 
of nanofibers represents one possible route to achieve effective drug absorption 
via mucosal surfaces. Potrč et al. formulated polycaprolactone (PCL) nanofibers 
intended for oromucosal delivery of poorly water-soluble drugs. In this study, 
two model drugs, ibuprofen and carvedilol, with similar lipophilic properties, but 
differing in their molecular weights were chosen, and their influence on the nano-
fiber’s physical properties and drug release profiles were investigated. The aim of 
the study was to establish a correlation between the drug’s properties and the release 
characteristics of a PCL nanofiber-based delivery system. The results obtained 
in this study have shown that electrospinning can be used for the fabrication of 
drug-loaded PCL nanofibers with a high percentage of API embedded in them. The 
formulation of poorly water-soluble drugs into polycaprolactone-based nanofibers 
significantly increases their dissolution rate. However, the release rate of drugs from 
nanofibers is drug-dependent. Electrospinning was shown to be a very promising 
approach to the formulation of poorly water-soluble drugs in order to enhance their 
release and enable oromucosal administration [46].
4.3 Transmucosal delivery of macromolecules and nanoparticle-based vaccines 
using nanofibers
Mucosal surfaces are the most convenient routes for drug delivery to systemic 
circulation. However, transmucosal transport of macromolecular drugs such as 
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peptides and proteins is much less effective as compared to low molecular weight 
drugs. Several strategies exploiting permeation enhancers, nanoparticulate carri-
ers, nanofibers, and their combinations represent a promising strategy to facilitate 
transmucosal transport of macromolecules.
Recently, nanofiber-based mucoadhesive films have been invented for oromucosal 
administration of nanocarriers used for delivery of drugs and vaccines (Figure 6).  
The mucoadhesive film consists of an electrospun nanofibrous reservoir layer, a 
mucoadhesive film layer, and a protective backing layer. The mucoadhesive layer 
made of HPMC and Carbopol 934P polymers is responsible for tight adhesion of the 
whole system to the oral mucosa after application. The electrospun nanofibrous res-
ervoir layer is intended to act as a reservoir for polymeric and lipid-based nanopar-
ticles, liposomes, virosomes, virus-like particles, dendrimers and the like, plus 
macromolecular drugs, antigens and/or allergens. The extremely large surface area of 
nanofibrous reservoir layers allows high levels of nanoparticle loading. Nanoparticles 
can either be reversibly adsorbed to the surface of nanofibers or they can be depos-
ited in the pores between the nanofibers. After mucosal application, nanofibrous 
reservoir layers are intended to promote prolonged release of nanoparticles into the 
submucosal tissue. Reversible adsorption of model nanoparticles as well as sufficient 
mucoadhesive properties was demonstrated. This novel system appears appropriate 
for the use in oral mucosa, especially for sublingual and buccal tissues [21].
Another example of novel multi-layered fibrous mucoadhesive film is based 
on self-assembled liposomes that are formed directly from nanofibrous layer after 
contacting with water. The idea came from a method of liposome preparation 
based on electrospinning technology. PVP was used as a nanofiber-forming matrix 
and phospholipid as liposome-forming molecules [47]. The membrane has been 
developed to improve the bioavailability of carvedilol. The whole system consists 
of an electrospun layer, an adhesive layer made of mucoadhesive film and a backing 
layer, similarly as previously described by Masek et al. [21]. Mucoadhesive film was 
formed using HPMC and CMC polymers and the standard solvent casting method. 
In general, this drug delivery system offered a novel platform for potential buccal 
delivery of drugs with a high first-pass effect.
One example for all macromolecular drugs is insulin. Insulin is a protein which 
is made of two polypeptide chains and it is not completely soluble in water. Many 
efforts have been made to find appropriate noninvasive routes of administration, 
including oral, pulmonary, rectal, oromucosal, and nasal. Although a certain degree 
of success exploiting all routes of mucosal administration of insulin was achieved, 
oromucosal, namely buccal and sublingual, delivery of insulin brings several 
Figure 6. 
Transmucosal penetration of model fluorescently labeled PLGA-PEG nanoparticles after ex vivo porcine 
mucosal administration using nanofibers. (A) PLGA-PEG nanoparticles (red) and (B) PLGA-PEG 
nanoparticles (red) plus nuclei (blue).
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advantages. A number of attempts have been made to improve buccal insulin 
absorption by adding absorption enhancers or to modify the lipophilicity of insulin.
It is important to note that buccal and sublingual delivery of macromolecules 
including insulin using rodents as an animal model are of no value, because oral 
mucosa of rodents is highly keratinized. Therefore, the permeability for macro-
molecules and nanoparticles is negligible, while that of humans is quite high in 
the non-keratinized areas (sublingual and buccal). It means that the only animal 
models that can be of use when studying the human permeability of oral mucosa for 
macromolecules is pigs or dogs.
Several drug delivery systems have been tested for oromucosal insulin delivery, 
including sprays, mucoadhesive gels, and mucoadhesive films.
Transmucosal delivery of insulin via oral mucosa represents a novel approach. 
As an example, Sharma et al. have prepared an electrospun nanofiber-based mem-
brane containing insulin molecules within the nanofiber structure. The solubility 
of insulin increases have been enhanced after formulation into polyvinyl alcohol 
(PVA) nanofibers as PVA itself is a surfactant and hence increases the solubility of 
insulin in the polymer solution. The release of insulin from a nanofiber membrane 
followed controlled release, and in vivo experiments confirmed high transmucosal 
delivery effectivity. Insulin release exhibits first order kinetics followed by an initial 
burst release necessary to produce the desired therapeutic activity. Furthermore, 
extremely high encapsulation efficacy of 99% of insulin indicates that nanofiber-
based delivery system serves as an ideal carrier for the delivery of insulin via the 
sublingual route [48].
4.4 Fast-dissolving nanofiber-based drug delivery systems
Fast-dissolving drug delivery systems (FDDS) represent advanced formula-
tions intended for oromucosal administration. FDDS are characterized by excellent 
flexibility and comfort for patients. The efficacy of drugs and rapid onset of their 
action are improved as FDDS dissolve within a minute in the oral cavity after the 
contact with saliva without the need of water for administration. FDDS are ben-
eficial especially in pediatric and geriatric patients. It is also useful for delivery of 
drugs with local action.
Li et al. have fabricated nanofiber-based FDDS by electrospinning using PVA as 
the nanofiber-forming polymer and drug carrier. Caffeine and riboflavin were used 
as the model drugs. They found that drug release was completed in a burst manner. 
100% of caffeine and 40% of riboflavin was dissolved within 60 s from the PVA 
nanofibrous matrices [49].
Isosorbide dinitrate-polyvinylpyrrolidone electrospun nanofibers were for-
mulated and explored as a potentially sublingual membrane by Chen et al. The 
composition was favorable for the fabrication of the sublingual membrane as the 
dissolution was completed at 120 s. The pharmacokinetic study in rats demon-
strated that the electrospinning fiber membrane had a higher Cmax and lower Tmax 
compared to the reference preparation [50].
Quan et al. demonstrated the concept of nanofiber-based FDDS also for poorly 
water-soluble drugs. In the study, feruloyl-oleyl-glycerol was used as a model drug 
and polyvinylpyrrolidone (PVP) K90 as a filament-forming polymer [51].
4.5 Mucosal administration sites of nanofiber-based drug delivery systems
Different mucosal sites of administration are a suitable target for nanofiber-
based drug delivery systems, including oromucosal, nasal, vaginal, and ocular 
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mucosa. Nanofiber-based drug delivery systems are used for both systemic and 
local drug administration.
4.5.1 Nanofibers in oromucosal drug delivery
Nanofiber membranes intended for oromucosal administration possess different 
properties according to the need of the desired indication and drug administered. 
The oromucosal site of administration, especially sublingual and buccal regions, 
are the most explored mucosal surfaces for drug delivery using the nanofiber-based 
system (Figure 7). The applications include fast-dissolving nanofiber-based formu-
lations, mucoadhesive nanofibers, nanofiber-based formulations of poorly water-
soluble drugs and, finally, nanofibers for delivery of different mucosal vaccines. 
Small drug molecules, macromolecules as therapeutic proteins, peptides, nucleic 
acids, and antigens are examples of the explored nanofiber-based systems intended 
for oromucosal administration. As description of these applications is broad, they 
are divided into relevant subchapters.
4.5.2 Nanofibers in vaginal drug delivery
Mucoadhesive nanofiber-based drug delivery systems are investigated for vagi-
nal drug delivery. A wide range of materials have been explored for their fabrication 
into nanofibers. However, the local environment of vaginal surface has to be taken 
into the account when designing nanofiber-based vaginal drug delivery systems. 
Especially, the low pH values around pH 4.0 ± 0.5 make the difference as compared 
to other mucosal surfaces. As an example, progesterone-loaded drug delivery 
nanofiber constructs are described in Chapter 4.1.2.
4.5.3 Nanofibers in nasal drug delivery
Supramolecular peptide nanofibers have been explored as nasal formulation 
for vaccines and immunotherapy. Si et al. performed a study eliciting the immune 
response without the use of adjuvants and without measurable inflammation. 
Peptides comprise an epitope from influenza polymerase and the Q11 self-assembly 
domain formed nanofibers which were taken up by dendritic cells in lung-draining 
mediastinal lymph nodes after intranasal immunization. Nanofibers administered 
onto nasal mucosa elicited higher antigen-specific CD8+ T cell responses in the 
lung-draining lymph nodes as compared to subcutaneous immunizations, while 
retaining the noninflammatory character of the materials as opposed to other 
delivery sites. Influenza vaccines that can be administered intranasally or by other 
needle-free delivery routes have potential advantages over injected formulations 
Figure 7. 
Application of multi-layered mucoadhesive film with nanofibrous reservoir layer to sublingual (A) and buccal 
(B) mucosa.
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in terms of patient compliance, cost, and ease of global distribution. It means that 
peptide nanofibers represent an interesting strategy for noninvasive influenza 
vaccines [52].
4.5.4 Nanofibers in ocular drug delivery
Ocular inserts are drug-impregnated formulations which can be placed onto 
ocular mucosa. Ocular inserts have been frequently used for reducing the frequency 
of administration, and, therefore, a controlled release profile is desired.
The objective of the study made by Mirzaeei et al. was to produce the electros-
pun nanofibers used as ophthalmic inserts. Triamcinolone acetonide was incorpo-
rated into a chitosan nanofiber-based ocular insert. This formulation increased the 
contact time between the drug and the conjunctival tissue, and thus decreased the 
number of administrations needed. This work showed that the concept of nanofi-
bers in ophthalmic drug delivery is feasible [53].
5.  Method of preparation and characterization of nanofibers for mucosal 
drug delivery
5.1 Fabrication of nanofibers for mucosal drug delivery
Nanofibers can be fabricated by several different techniques including drawing 
[54], phase separation [55], nanofiber seeding [56], template synthesis [57], self-
assembly [58], etc. These techniques, on the other hand, allow neither control of 
nanofiber diameter nor continuous nanofiber production. Moreover, such tech-
niques can only be used with specific polymers. On the contrary, electrospinning 
[59] is a resourceful and cost-effective technique that can be used to synthesize con-
tinuous nanofibers from numerous polymers and efficiently control their diameter.
Specifically, nanofibers produced by electrospinning (electrospun nanofibers) 
may be prepared from soluble polymers or from polymer solutions modified with 
additives such as particles, antimicrobial agents, or enzymes. Thanks to these 
additives, electrospun nanofibers may have desired properties. Therefore, electros-
pinning has gained a remarkable popularity in various disciplines boosting a recent 
steep rise in numbers of scientific publications.
Technically, electrospinning is a process that uses a strong electrical field to draw 
a polymer fluid into fine filaments. A typical electrospinning setup only requires a 
high voltage power supply, a syringe, a flat tip needle, and a conducting collector. 
When a polymer solution is charged with a high voltage, electrostatic force draws 
the fluid into a liquid jet (Figure 8A). Finally, solvent evaporation from the fila-
ments results in solid nanofibers. In most cases, as-spun fibers deposit randomly on 
the electrode collector forming a nonwoven nanofiber mat. The basic equipment 
can be modified for various applications such as dual needle syringe (to make 
blended fibers), rotating collectors, etc.
Nanospider technology is a modern electrospinning technology for industrial-
scale production of nanofibrous material without nozzles, needles, or spinnerets. 
Nanospider technology uses simply shaped electrodes covered by polymer solution 
(Figure 8B). It results in a mechanically simple technology with no parts that can 
be easily clogged (in comparison to needle-type electrospinning). Proven by an 
industrial operation, Nanospider technology provides high efficiency, outstanding 
fiber diameter, and web uniformity.
By electrospinning process it is possible to produce continuous nanofibers from 
a wide range of polymers. However, there are several parameters affecting the fiber 
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morphology and properties of electrospun nanofibers. The whole process can be 
controlled by four important characteristics: (i) process parameters such as volt-
age, spinning distance, flow rate, or collecting plate, (ii) systemic and (iii) solution 
parameters which affected concentration, conductivity, or surface tension of a 
polymer solution, and (iv) physical parameters such as humidity, temperature, or air 
velocity. All mentioned parameters are major factors affecting the fiber morphology 
and web properties. Because these variables interrelate, a small change in either of 
these variables can have a significant impact on nanofiber morphology or even the 
electrospinning process altogether. Solvents or their mixtures used for dissolving of 
polymer have a direct impact on the electrospinning process and morphology of the 
resulting nanofibers. Laboratory experience has shown that a solvent that creates 
mostly 80–99 wt% of polymer solution has a dominant impact. Solvents primarily 
determine (i) conformation of dissolved macromolecular chains, (ii) easiness of 
charging the surface layer, (iii) cohesion of the polymer solution due to the surface 
tension forces, and (iv) the rate of solidification of the liquid jet during evaporation 
of the solvent.
5.2 Materials suitable for nanofiber-based mucosal drug delivery systems
Nanofiber-based mucosal drug delivery systems cannot be in general electro-
spun from any polymer as they require specific properties. As examples of very 
interesting materials for nanofiber-based mucosal drug delivery systems, the fol-
lowing can be mentioned: biopolymers such as gelatin [60], chitosan [31], collagen 
[61], cellulose [62], silk fibroin [63], hyaluronic acid [64], polylactic acid [65], or 
polycaprolactone [46].
In addition to specific materials used for production of nanofiber mucosal drug 
delivery systems they also require surface modification of nanofibers. After the 
functionalization of a nanofiber surface, drugs might be bound or conjugated to 
nanofiber surfaces. In such a way, the release of drugs would be attenuated, and the 
functionality of the surface-immobilized biomolecules could be preserved. This 
strategy is usually applied in order to overcome the issue of initial burst release as 
well as short release time. The most used surface modifications are: (i) plasma treat-
ment, (ii) wet chemical method, or (iii) co-electrospinning of active agents.
Different sources of plasma (e.g., oxygen, argon, ammonia, air) used for 
treatment of nanofibers can create different functional groups (such as carboxyl or 
amine groups) on the nanofiber surface. This kind of chemical groups may interact 
with particular drugs and create covalent bonds. However, if a target biomolecule 
is chemically bound onto the nanofiber surface, it would hardly be released. 
Figure 8. 
Schematic representation of an electrospinning process (A): (1) a high voltage supply, (2) a grounded collector 
of nanofibers, (3) a polymer solution, and (4) a positive electrode. Schematic representation of Nanospider 
technology (B): (1) a polymer solution, (2) a rotating electrode with a high voltage supply, (3) created 
nanofibers, and (4) a grounded collector of nanofibers.
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Therefore, this technique is more suitable for drugs, where a slow and prolonged 
release of the agent is required. Plasma treatment can also change hydrophilicity 
and hydrophobicity of nanofibers.
Wet chemical method allows changing the wettability of nanofibers under 
acidic or basic conditions. Surface of nanofibers deep in mesh can also be modified 
by the wet chemical method. Plasma treatment is, on the contrary, more suitable 
for flat materials.
By co-electrospinning of active agents, it is possible to directly expose biologi-
cal functional agents on the surface of nanofibers. Conjugating the biomolecules 
(DNA, growth factors, or enzymes) to the fiber surfaces allows their slow release 
into a nearby tissue significantly preserving the functionality of biomolecules.
Functionalization of the nanofiber surface enables loading of drugs. There are 
many methods how to load them. The most popular and used techniques are:  
(i) physical adsorption, (ii) nanoparticle assembly method, (iii) layer by layer 
method, and (iv) chemical immobilization.
In the case of physical adsorption, there is no need for nanofiber functional-
ization after electrospinning. The fiber web is simply immersed into a solution 
containing drugs and dried afterward. The same method can be used in the case 
of nanoparticles containing biological agents. Chemical immobilization requires 
functionalized surface of nanofibers by the plasma treatment or chemical wet 
method. Afterward, functional groups on the surface of nanofibers chemically react 
with added drugs and create covalent bonds. By the multilayer method, it is possible 
to produce a nanofiber sandwich with different properties on both surfaces. After 
electrospinning of one layer with drugs added during the electrospinning process, a 
sandwich with another nanofiber layer without drugs can be created.
5.3 Methods for characterization of nanofibers for mucosal drug delivery
Biomedical applications of nanofibers such as the mucosal drug delivery system 
put special requirements on the three-dimensional electrospun materials. Besides 
the biocompatibility, the morphology of nanofibers is one of the most important 
attributes. The specific surface area, volume, and the size of the pores have consid-
erable effect on the loading capacity of drugs. The following methods are used to 
characterize electrospun materials for mucosal drug delivery systems.
Imaging methods are used for evaluation of nanofiber structure. Imaging meth-
ods involve scanning electron microscopy (SEM), transmission electron microscopy 
(TEM), and atomic force microscopy (AFM). By SEM and TEM, it is possible to 
evaluate the nanofiber orientation, nanofiber diameter, and the morphology of 
nanofibers, which do not only affect the mechanical properties of electrospun 
materials, but also play a key role in the loading capacity of drugs in the mucosal 
drug delivery systems. Imaging methods also allow visualization of the morphology 
of nanofibers at various points of an electrospun material.
Loading of drugs must be controlled during the assessment of biological proper-
ties and this ability is significantly affected by the physical properties such as pore 
size and volume of electrospun material. The surface area and the porosity could 
be measured by mercury porosimetry or by Brunauer-Emmett-Teller (BET) surface 
area analysis. A pore size distribution is one of the most often presented results of 
mercury porosimetry. However, the mercury porosimetry can produce a misleading 
result due to the mechanical deformation of the nanofibers [66]. To overcome this 
issue, BET measurements are used to measure the specific surface area value and 
distribution of pores.
Besides the morphology of nanofibers, the chemical composition is an impor-
tant attribute for materials applicable in the mucosal drug delivery systems. The 
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Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry 
(DSC) [67], and differential thermal analysis (DTA) are essential methods for 
measuring the chemical composition. These methods allow detection of abundance 
of each polymer in the final product. FTIR indicates degradation of nanofibers (for 
biodegradable materials) as well as it may show their bioactivity. The bioactivity 
is detected by infrared spectra obtained via FTIR that identifies the functional 
chemical groups. The hydrophilic/hydrophobic character of electrospun materials 
influences the loading capacity of nanofibers as well. To determine the degree of 
hydrophilicity, contact angle measurement is one of the most used methods.
The last most important and crucial characteristic of nanofibers is the release 
of drugs from electrospun materials [68]. As it was mentioned above, slow or fast 
release of target drugs might be changed by a different surface functionalization of 
nanofibers. For this purpose, a dissolution testing apparatus with UV-Vis spectro-
photometer is essential to control the release profile.
6. Conclusions and future directions
Different parts of the human body are covered by mucosa with different features, 
barrier properties for drug delivery, and also with different accessibility. Formulation 
of drugs into nanofibers represents one of the new trends in mucosal drug delivery. 
Due to their extremely large surface area, unique surface topology and porosity, 
nanofiber-based drug delivery systems enable transmucosal delivery of poorly water-
soluble drugs, macromolecules, nanoparticles, and vaccine delivery carriers.
Extraordinary flexibility of nanofibers enables us to follow unique anatomical 
specialities of mucosal surfaces, and hence helps to overcome different absorption 
barriers of mucosal sites. Moreover, the flexibility of nanofibers helps to significantly 
increase the comfort of nanofiber-based drug delivery formulations for patients.
Mucoadhesive nanofibers with drug-controlled release properties and nanofi-
bers with extremely fast-dissolving properties are examples of a great variety of 
nanofiber-based materials and also examples of a variety of drug delivery system 
properties advantageous for mucosal administration. Different mucosal sites of 
administration, including sublingual, buccal, nasal, vaginal, and ocular mucosa, are 
suitable targets for nanofiber-based drug delivery systems. Mucosal surfaces, as a 
portal of entry of various infectious pathogens, naturally possess great potential for 
induction of defensive immune responses against such pathogens. Nanofiber-based 
delivery platforms, owning their unique properties, may play an important role in 
formulation of antigens into next-generation vaccine delivery systems intended for 
mucosal administration.
Technologies of electrospinning, such as Nanospider technology, are modern 
electrospinning technologies enabling cost-effective industrial-scale produc-
tion of nanofibrous materials, among others, suitable for mucosal drug delivery 
applications.
Combinations of nanofiber-based formulations and chemical enhancers have a 
great potential to increase penetration of drug molecules and nanoparticle-based drug 
and vaccine delivery systems. In conclusion, nanofibers represent a new emerging 
trend in formulation of drug and vaccine delivery systems for mucosal administration.
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